ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Gene Expression"

  • Abstract Number: 0039.5 • ACR Convergence 2023

    Cytokine-induced Transcriptome Modification Elucidates the Similarity and Dissimilarity Across 10 Immune-related Diseases

    Haruka Takahashi1, Hiroaki Hatano2, Masahiro Nakano3, Haruka Tsuchiya4, Mineto Ota4, Tomohisa Okamura5, Keishi Fujio4 and Kazuyoshi Ishigaki6, 1Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences and Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, 3Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, 4Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 5Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 6RIKEN, Tokyo, Japan

    Background/Purpose: Abnormal cytokine regulation is the fundamental pathology of immune-mediated diseases (IMDs). Clinical transcriptome data has a potential to monitor real-time cytokine pathway activities of…
  • Abstract Number: 1668 • ACR Convergence 2023

    Cell Specific Molecular Profiling of Scleroderma Associated Interstitial Lung Disease Subtypes

    Monica Yang1, Fred Deiter1, Emily Flynn1, Jessica Neely1, Seoyeon Lee2, John Greenland1, Marina Sirota3 and Paul Wolters1, 1University of California San Francisco, San Francisco, CA, 2Yale University School of Medicine, New Haven, CT, 3Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA

    Background/Purpose: Interstitial lung disease (ILD) is present in up to 90% of patients with systemic sclerosis (SSc) and the leading cause of SSc-related mortality. SSc-ILD…
  • Abstract Number: 0079 • ACR Convergence 2023

    CD4 T Cell Repertoire Features in RA Patients with High-risk HLA-DRB1 Alleles

    Amit Lakhanpal1, Kazuyoshi Ishigaki2, Anvita Singaraju1, Alejandro Kochen3, Miriam Fein1, Soumya Raychaudhuri4 and Laura Donlin1, 1Hospital for Special Surgery, New York, NY, 2RIKEN, Tokyo, Japan, 3Yale School of Medicine, New Haven, CT, 4Brigham and Women's Hospital, Boston, MA

    Background/Purpose: A role for CD4 T cells in RA pathology is supported by the effectiveness of T cell therapies, genetic studies implicating T cell gene…
  • Abstract Number: 1695 • ACR Convergence 2023

    Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis

    Philip Carlucci1, Jasmine Shwetar2, Siddarth Gurajala3, Qian Xiao3, Joseph Mears4, Katie Preisinger1, Devyn Zaminski5, Kristina Deonaraine1, Peter Izmirly1, Andrea Fava6, Judith James7, Joel Guthridge7, Brad Rovin8, Sethu Madhavan8, Wade DeJager7, David Wofsy9, Ming Wu2, Chaim Putterman10, Deepak Rao11, Betty Diamond12, Derek Fine13, Jose Monroy-Trujillo13, Kristin Haag14, H Michael Belmont5, William Apruzzese11, Anne Davidson12, Fernanda Payan-Schober15, Richard Furie16, Paul Hoover11, Celine Berthier17, Maria Dall'Era9, Kerry Cho18, Diane L. Kamen19, Kenneth Kalunian20, Jennifer Anolik21, Arnon Arazi22, Soumya Raychaudhuri11, Nir Hacohen23, Michelle Petri24, Robert Clancy25, Kelly Ruggles2, Jill Buyon25 and The Accelerating Medicines Partnership in RA/SLE26, 1New York University School of Medicine, New York, NY, 2NYU Langone, New York, NY, 3Harvard Medical School, Boston, MA, 4Michigan University, Ann Arbor, MI, 5NYU School of Medicine, New York, NY, 6Johns Hopkins University, Baltimore, MD, 7Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Ohio State University, Columbus, OH, 9University of California San Francisco, San Francisco, CA, 10Albert Einstein College of Medicine, Bronx, NY, 11Brigham and Women's Hospital, Boston, MA, 12Feinstein Institutes for Medical Research, Manhasset, NY, 13Johns Hopkins School of Medicine, Baltimore, MD, 14Thomas Jefferson University, Philadelphia, PA, 15Texas Tech University Health Sciences Center, El Paso, TX, 16Northwell Health, Manhasset, NY, 17University of Michigan, Ann Arbor, MI, 18UCSF Health, San Francisco, CA, 19Medical University of South Carolina, Charleston, SC, 20University of California San Diego, La Jolla, CA, 21University of Rochester Medical Center, Rochester, NY, 22Broad Institute of MIT and Harvard, Melrose, MA, 23Broad Institute of MIT and Harvard, Cambridge, MA, 24Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 25NYU Grossman School of Medicine, New York, NY, 26Multiple, Bethesda, MD

    Background/Purpose: The G1 and G2 risk variants (RVs) in Apolipoprotein L1 (APOL1) associate with CKD and may contribute to poorer outcomes for African American (AA)…
  • Abstract Number: 0112 • ACR Convergence 2023

    Molecular Stratification of Antiphospholipid Syndrome Patients Through Integrative Analysis of the Whole-blood RNA Transcriptome

    Amala Ambati1, Feiyang Ma1, Katarina Kmetova1, Sherwin Navaz1, Claire Hoy1, Cyrus Sarosh1, Ajay Tambralli1, Johann E. Gudjonsson1, J. Michelle Kahlenberg1, Jacqueline Madison1, Ali Duarte-Garcia2, Jason Knight1 and Yu Zuo1, 1University of Michigan, Ann Arbor, MI, 2Mayo Clinic, Rochester, MN

    Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease associated with diverse clinical manifestations in the setting of persistent antiphospholipid antibodies (aPL). Early diagnosis and…
  • Abstract Number: 1709 • ACR Convergence 2023

    Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction

    Jessica Turnier, Celine Berthier, Sarah Vandenbergen, Christine Goudsmit, Madison McClune, Johann E. Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…
  • Abstract Number: 0114 • ACR Convergence 2023

    Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS

    Yu Shi1, Xiaofan Luo2, Quan Chen3, Jiuliang zhao4, Mengtao Li4 and xiaofeng Zeng5, 1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Nankai University, Tianjin, China, 3Nankai University, Beijing, China, 4Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 5Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Platelets play a pivotal role in the process of coagulation and other biological process. Studies have shown multiple evidences that platelets are highly activated…
  • Abstract Number: 1738 • ACR Convergence 2023

    Identification of Homeostatic and Inflammatory Synovial Fibroblast Signatures in Synovial Tissue Biopsies of Healthy Controls and Patients with Rheumatoid Arthritis

    Brianne Barker1, Órla Tynan2, Conor Smith3, Dumitru Anton4, Carl Orr5, Mary Canavan6, Douglas Veale7 and Ursula Fearon8, 1Molecular Rheumatology, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Rheumatic and Arthritic Diseases, St Vincent's University Hospital, University College Dublin, Dublin, Ireland, 2Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 3Translational Immunology, Trinity Biomedical Sciences Institute, Dublin, Ireland, 4Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 5EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 6Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, 7St.Vincent's University Hosp, Dublin, Ireland, 8Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Recent literature has identified different synovial fibroblast (FLS) populations within RA synovium with distinct inflammatory profiles. Despite current advances in classifying heterogeneity of FLS…
  • Abstract Number: 0265 • ACR Convergence 2023

    Differential and Combinatorial Mechanism of Action of Golimumab and Guselkumab in Ulcerative Colitis Induction Therapy: IL-23 Blockade Drives Restoration of Normal Epithelium and Mucosal Healing

    Prerak Desai1, Patrick Branigan2, Dylan Richards1, Dennis McGonagle3, Marion Vetter1, Daniel J. Cua1 and Thomas Freeman1, 1Janssen Research & Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Minneapolis, MN, 3Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: The combination treatment of golimumab (GOL), a tumor necrosis factor-alpha (TNFα) antagonist, and guselkumab (GUS), an interleukin (IL)-23 inhibitor was shown to induce higher…
  • Abstract Number: 1762 • ACR Convergence 2023

    Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls

    JING SONG1, Cliff Rims1, Matthew Dufort1, Peter Linsley1, Eddie James2 and Jane Buckner2, 1Benaroya Research Institute, Seattle, WA, 2Benaroya Research Institute at Virginia Mason, Seattle, WA

    Background/Purpose: Single-cell analysis has emerged as a powerful tool for investigating the transcriptomics and T-cell receptor (TCR) diversity in patients with rheumatoid arthritis (RA). However,…
  • Abstract Number: 016 • 2023 Pediatric Rheumatology Symposium

    Gene Expression Changes in Polyarticular Juvenile Idiopathic Arthritis Following Tofacitinib Treatment

    Esraa Eloseily1, Alex Pickering2, Sanjeev Dhakal3, Alexei Grom3, Hermine Brunner3 and Sherry Thornton4, 1Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnti, OH, 2Department of Biomedical Informatics, Harvard Medical School, Boston, MA, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Despite advances in the understanding of juvenile idiopathic arthritis (JIA) pathophysiology, personalized treatments informed by gene transcriptomic profiles remain elusive. We aimed toexamine the…
  • Abstract Number: 081 • 2023 Pediatric Rheumatology Symposium

    Predicting Extension in Juvenile Idiopathic Arthritis

    Megan Simonds1, Kathleen Sullivan2 and AnneMarie Brescia1, 1Nemours Children's Health, Wilmington, DE, 2Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood and carries a risk of permanent joint damage and disability [1]. In…
  • Abstract Number: L04 • ACR Convergence 2022

    Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis

    Maria de la Luz Garcia-Hernandez1, Javier Rangel-Moreno1, Ananta Paine2, Soumyaroop Bhattacharya3, Jeffrey Fox4, Ernest Meyer5, Brian Isett5, Riyue Bao6, Tullia Bruno6 and Christopher Ritchlin7, 1University of Rochester, Rochester, NY, 2ORNA Tx, Southborough, MA, 3Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, 4CMSR, University of Rochester Medical Center, Rochester, NY, 5UPMC Hillman Cancer Center, Pittsburgh, PA, 6University of Pittsburgh, Pittsburgh, PA, 7University of Rochester Medical Center, Rochester, NY

    Background/Purpose: A pivotal clinical characteristic of psoriatic arthritis (PsA) is disease manifestations in several domains (skin, entheses, joints, spine) and multiple domain involvement is prevalent,…
  • Abstract Number: 0046 • ACR Convergence 2022

    Baricitinib Ameliorates Residual Neuropathic Pain in Collagen Antibody-Induced Arthritis Mice by Suppressing Inflammation of the Dorsal Root Ganglion

    Kenta Makabe1, Yasunori Omata1, Hiroyuki Okada1, Ryota Chijimatsu2, Asuka Terashima1, Fumiko Yano1, Sakae Tanaka1 and Taku Saito1, 1Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Okayama, Japan

    Background/Purpose: In clinical trials for the treatment of rheumatoid arthritis, baricitinib was shown to significantly improve pain scores compared with anti-TNF inhibitors. This result suggests…
  • Abstract Number: 0607 • ACR Convergence 2022

    Cadherin 6 Regulates Rheumatoid Arthritis Fibroblasts-Like Synoviocyte Aggressiveness

    Camilla Machado1, Hyeonjeong Lee2, Sho Sendo3, Narayanan Perumal4, Wei Wang5, David Boyle5 and Gary S. Firestein6, 1UCSD, San Diego, CA, 2University of California San Diego, San Diego, CA, 3University California, San Diego (UCSD), La Jolla, CA, 4Eli Lilly Company, San Diego, 5University of California San Diego, San Diego, 6University of California, San Diego, San Diego, CA

    Background/Purpose: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) display an aggressive behavior. Previous studies have implicated cadherins in FLS function in this phenotype, which are type…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 31
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology